Premium Content
Repligen’s deal for BioLife Solutions indicates shift to manufacturing integration
Repligen’s $1.5bn purchase of BioLife Solutions adds CryoStor biopreservation to its bioprocessing portfolio, underscoring pharma’s shift toward integrated cell and gene therapy supply chains.
Health tech’s role in obesity to expand beyond a ‘nice-to-have’
Experts predict that DHTs such as wearables and health apps will play a burgeoning role in obesity research and care, though barriers to equitable access remain.
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.
Orexin receptor agonists set to propel narcolepsy treatment into a new era
With several narcolepsy treatments advancing, the race for market leadership remains open.
What will health and social care look like under Andy Burnham?
This report examines some of the early signals emerging from the new Burnham Labour government and explores what it could mean for the NHS and the healthcare technology market.